Genmab A/S (CPH:GMAB)
1,668.00
-22.50 (-1.33%)
May 19, 2026, 12:14 PM CET
Genmab Market Cap
Genmab has a market cap or net worth of 103.79 billion as of May 19, 2026. Its market cap has increased by 23.65% in one year.
Market Cap
103.79B
Enterprise Value
128.59B
Revenue
25.29B
Ranking
n/a
PE Ratio
19.89
Stock Price
1,668.00
Market Cap Chart
Since October 18, 2000, Genmab's market cap has increased from 3.68B to 103.79B, an increase of 2,717.04%. That is a compound annual growth rate of 13.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 13, 2026 | 103.39B | -17.20% |
| Dec 30, 2025 | 124.86B | 31.70% |
| Dec 30, 2024 | 94.81B | -32.65% |
| Dec 29, 2023 | 140.77B | -26.77% |
| Dec 30, 2022 | 192.23B | 11.72% |
| Dec 30, 2021 | 172.06B | 6.80% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Novo Nordisk | 1.33T |
| Coloplast | 91.03B |
| ALK-Abelló | 56.01B |
| Demant | 48.80B |
| H. Lundbeck | 38.77B |
| Zealand Pharma | 21.94B |
| Ambu A/S | 16.54B |
| Bavarian Nordic | 14.40B |